Astellas Reports the Submission of NDA to the US FDA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause
Shots:
- The company has submitted an NDA to the US FDA for fezolinetant in patients with mod. to sev. VMS associated with menopause
- The NDA submission was based on the P-III (SKYLIGHT 1 & 2) in 1000 women for the first 12wks. followed by a 40wk. treatment extension period along with the P-III (SKYLIGHT 4) study in 1800 women for 52wk. evaluating fezolinetant to treat mod. to sev. VMS at ~180 sites within the US, Canada & EU
- Fezolinetant is an oral, nonhormonal compound indicated for VMS associated with menopause & blocks NKB binding on the KNDy neuron to mod. neuronal activity in the thermoregulatory center of the brain to reduce the frequency & severity. The financial effects of this submission for Mar 2023 are being assessed by Astellas
Ref: Astellas | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
